Merck & co

PROJECT REPORT ON MERCK & CO

INTRODUCTION
One of the largest pharmaceutical company in the world both by market capitalization & revenue
Established in 1891 as the United States subsidiary of the German company now known as Merck KGaA
1917 as an independent company
Manufactures & markets broad range of products to improve human & animal health

BASIC INFORMATION
Industry
Founded
Headquaters
Chairman
President & CEO
Pharmaceuticals
1891 as a subsidiary of Merck KGaA
Whitehouse Station, New Jersey, United States
Richard T. clarck
Stanley F. Barshay

CONTINUED
Revenue
Operating Income
Net Income
Total assets
Total equity
Employees
US$27.4 Billion
US$4.83 Billion
US$12.9 Billion
US$112 Billion
US$59.1 Billion
61,500

VISION OF MERCK & CO.
We make a difference in the lives of people globally through our innovative medicines, vaccines, and consumer health and animal products. We aspire to be the best healthcare company in the world and are dedicated to providing leading innovations and solutions for tomorrow.

MISSION OF MERCK & CO
To provide innovative, distinctive products and services that save and improve lives and satisfy customer needs, to be recognized as a great place to work, and to provide investors with a superior rate of return.

WHAT WE STAND FOR ????
Excellence in science and healthcare innovation, with an emphasis on addressing unmet medical needs.
Focus on patients and anticipating customers needs

CONTINUED
Commitment to expand access to our medicines and vaccines, and to improve global health

PRODUCTS WE DEAL IN ….
VACCINES
PRESCRIPTION PRODUCTS
CONSUMER PRODUCTS
ANIMAL HEALTH
PRESCRIBING INFORMATION

RESPONSIBILITY OF MERCK & CO.
ETHICS & TRANSPARENCY
ACCESS
ENVIRONMENT
COMMUNITY

OBJECTIVE OF MERCK & CO
To develop policy positions that guide our activities and advocacy on a range of issues
To seek opportunities to adopt industry-leading standards in several areas
To strive to communicate clearly and transparently about our positions

CONTINUED
To work closely with the many groups and individuals who are also trying to address the complex healthcare challenges that confront us

PRODUCTS ON THE MARKET
Antivenin - for the treatment of Black Widow Spider bites
Arcoxia (etoricoxib) - for the symptomatic treatment of osteoarthritis
Cancidas (caspofungin) - An echinocandins antifungal drug for treatment of Aspergillus and Candida

CONTINUED
Cosopt (dorzolamide and timolol) - reduces intraocular pressure in people with glaucoma or ocular hypertension.
Cozaar/Hyzaar (losartan)- used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy.

CONTINUED
Cozaar/Hyzaar (losartan)- used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy.
Crixivan (indinavir) – a protease inhibitor HIV medication.
Emend (aprepitant) – treats vomiting and nausea brought about by chemotherapy.

CONTINUED
Emend (aprepitant) – treats vomiting and nausea brought about by chemotherapy
Emend Injection (fosaprepitantdimeglumine) - an intravenous drug for nausea and vomiting caused by chemotherapy
Emflex (Acemetacin) - a non-steroidal anti-inflammatory drug

CONTINUED
Fosamax (alendronate) – osteoporosis medication.
Fosamax Plus D (alendronate/vitamin D) – osteoporosis medication
Isentress (raltegravir) - HIV integrase inhibitor.

COMMON ST. OF MERCK & CO

REVENUE GRAPH OF MERCK & CO.

COMPETITORS IN UK
NAMEOF THE COMPANY
TOTAL REVENUE
(IN USD BILLIONS)
45.83
32.81
GlaxoSmithKline
AstraZeneca

COMPETITORS IN USA
NAME OF THE COMPANY
Johnson & Johnson
Abbott Laboratories
Pfizer
Eli lilly
Bristol-Myers Squibb
TOTAL REVENUE(IN USD BILLIONS )
61.90
30.76
50.0
21.84
18.81

COMPETITORS IN SWITZERLAND
NAME OF THE COUNTRY
HOFFMAN LA ROCHE
NOVARTIS
NYCOMED
TOTAL REVENUE
(IN USD BILLIONS)
47.35
44.27
4.26

COMPETITORS IN GERMANY
NAME OF THE COUNTRY
BAYER
BOEHRINGER INGELHEIM
MERCK kGaA
TOTAL REVENUE
(IN USD BILLIONS)
22.3
16.9
5.17

COMPETITORS IN JAPAN
NAME OF THE COUNTRY
TAKEDAPHARMACEUTICAL
ASTELLAS PHARMA
DAIICHI SANKYO 9
EISAI
CHUGAI PHARMACEUTICAL .
TOTAL REVENUE
(IN USD BILLIONS)
15.6
10.7
9
5.5
2.0

SELECTIVE PRODUCT :LISINOPRIL
It is a drug of the angiotensin converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension, congestive heart failure, heart attacks and also in preventing renal and retinal complications of diabetes. It has been compared withomapatrilat which is of similar function.

SYSTEMATIC IMAGE

IDENTIFIERS
CAS number
ATC code
PubChemode
8C09AA03
3915-83-7
CID 5362119

CHEMICAL DATA
Formula
Mol. Mass
SMILES
InChISynonyms
C21H31N3O5
405.488 g/mol
Emolecules & Pubchem
(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid

Pharmacology
Lisinopril is the lysine-analog of enalapril
Lisinopril is not a pro drug and is excreted unchanged in the urine
In cases of overdosage, it can be removed from circulation by dialysis

CLINICAL USE
Its indications, contraindications and side effects are as those for all ACE inhibitors
Its long half-life allows for once a day dosing which aids patient compliance
Patients whose creatinine clearance ≥10 mL/min and ≤30 mL/min should be given the standard 5 mg/day dosage, at first

CONTINUED
For patients whose creatinine clearance is less than 10 mL/min, the dosage should start at 2.5 mg/day, adjusted over time according to the patient's blood pressure response

ADVERSE EFFECTS
Chills, infection
Dark urine, decreased urination
Difficulty swallowing or breathing
Hoarseness
Itching

CONTINUED
Rapid weight gain, stomach pain
Yellowing of skin or eyes (jaundice)
Abdominal pain, bloating, vomiting
Chest pain or tightness, dizziness, lightheadedness, fainting (syncope)

CONTINUED
Dry cough
Fever
Joint pain
Rash
Diarrhea, loss of taste, nausea

REVENUE OF LISINOPRIL

MARKET SHARE OF LISINOPRIL

Thank You
Presented By :-
REEMA PUNIANI
(M100700046)

Merck & co

by Reema Puniani on Dec 10, 2010

Accessibility

Categories

Upload Details

Usage Rights

Statistics

Merck & co — Presentation Transcript